AAP 2027
Cluster Santé–
Horizon Europe

Pour discuter d’une idée de projet ou mieux connaitre les modalités de participation et d’accompagnement:

cellule.europe@inserm.fr

Inserm

WP 2026-2027 CLUSTER SANTE

WP26-27 Cluster Santé officiel

2027
17 AAP
Deadline: 17 février 2027

Inserm

Destination 3				
HORIZON-HLTH-2027-01-DISEASE-05: **Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential**	2027 – 1 étape RIA	5 projets 9-11 M€/projet	Development of novel or existing broad spectrum antiviral candidates Discovery and selection of candidate antivirals, Optimisation of selected candidates, In vitro characterisation of antiviral activity, mechanism of action In vivo tests in at least one animal model (or, if available in human organoid or organotypic models) If requested by regulators as pre-requisite for clinical studies, in vivo tests in a non-human primate model Production of batches (GMP standard) First in human clinical safety studies	• Junin mammarenavirus and/or Lassa mammarenavirus • Tick-borne encephalitis virus and/or • Japanese encephalitis virus • Andes virus and/or Hantaan virus and/or Sin Nombre virus • Hendra virus • Enterovirus D68 • Venezuelan equine encephalitis virus Antibodies and antibody derived proteins excluded

Destination 3				
HORIZON-HLTH-2027-01-DISEASE-06: : **Development of monoclonal antibodies to prevent and treat infections from Flaviviruses**	2027 – 1 étape RIA	4 projets 9-10 M€/projet	Development of existing prophylactic and therapeutic monoclonal antibody candidates Finalisation of the in vitro characterisation of existing monoclonal antibody candidates In vivo tests in at least one animal model (or, if available in humanised immune system animal models) If requested by regulators as pre-requisite for clinical studies, in vivo tests in a non-human primate model. Evaluation of antibody-dependent enhancement (ADE) risk Production of batches of the most promising antibody candidates (GMP standard) First in human clinical safety studies	• Dengue Virus, • Tick-borne Encephalitis Virus, • Japanese Encephalitis Virus, • West Nile Fever Virus, • Yellow Fever Virus • Zika Virus

Destination 3				
HORIZON-HLTH-2027-01-DISEASE-07: **Development of monoclonal antibodies to prevent and treat infections from Filo- Phenui-, Picorna- and Toga Viridae**	2027 – 1 étape RIA	4 projets 9-10 M€/projet	Development of existing prophylactic and therapeutic monoclonal antibody candidates Finalisation of the in vitro characterisation of existing monoclonal antibody candidates In vivo tests in at least one animal model or, if available in humanised immune system animal models If requested by regulators as pre-requisite for clinical studies, in vivo tests in a non-human primate model. Evaluation of antibody-dependent enhancement (ADE) risk Production of batches of the most promising antibody candidates under GMP First in human clinical safety studies	• Ebola Virus • Marburg Virus • Crimean-Congo Hemorrhagic Fever Virus • Rift Valley Fever Virus • Enterovirus D68 • Chikungunya Virus

Destination 3				
HORIZON-HLTH-2027-01-DISEASE-08: **Development of innovative antimicrobials against critical pathogens resistant to antimicrobials (AMR)**	2027 – 1 étape RIA	5 projets 8-10 M€/projet	Development of innovative and effective antibacterial and antifungal agents, including antibody-based therapies Accelerate testing of novel candidates in human trials Finalisation of in vivo tests in at least one animal model (or, if available in humanised immune system animal models) to demonstrate the protective function of the therapeutics deemed sufficient for moving to first clinical trials. If requested by regulators as enablers for clinical studies, in vivo tests in a non-human primate model. Production of batches of the most promising antimicrobials candidates (GMP) In human clinical safety and efficacy studies	**At least 1 on the following critical pathogens**: Carbapenem resistant Acinetobacter Baumanii (CRAB). Carbapenem-resistant Enterobacterales (CRE) and third-generation cephalosporin-resistant Enterobacterales (C3GRE) Carbapenem resistant Pseudomonas Aeruginosa. Methicillin-Resistant Staphylococcus aureus (MRSA) (Drug)-resistant Aspergillus fumigatus (Drug)-resistant *Candida spp.* Not pursue the development of phage-therapies

CLUSTER SANTE – WP 2026-2027

Destination 6

Industrie de la santé de l'UE soit innovante, durable et compétitive au niveau mondial grâce à une meilleure adoption des technologies et innovations de rupture

HORIZON-HLTH-2027-02-IND-02-twostage: **Portable and versatile Point-of-care diagnostics**	2027 – 2 étapes IA	6 projets 5-7M€/projet	-• **The optimization of (the) targeted POC in-vitro diagnostic device(s)** that take(s) the above-mentioned criteria, challenges and aspects into consideration; • **The elaboration of a comparative study clearly demonstrating the added value and improved performance of the optimized POC in-vitro diagnostic device(s)** as compared to the current state of the art for the targeted diagnostic application; • **The conduct of clinical studies of (the) optimized POC in-vitro diagnostic medical device(s)** as a preferred information source for their clinical validation; subsequent conformity assessment in agreement with requisite regulatory requirements of the EU's IVDR or MDR regulatory requirements.	• **In case of targeting infectious diseases**, priority should be given to approaches enabling the distinction between viral, bacterial or fungal infections. • **In case of targeting non-communicable diseases**, priority should be given to approaches that are used in emergency rooms where decisions can have life-saving character. -

Deadline (1ère étape): 17 février 2027
Deadline (2ème étape): 16 septembre 2027

Inserm